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Abstract
Complement	peptide	receptors	(nomenclature	as	agreed	by	the	NC-IUPHAR	subcommittee	on
Complement	peptide	receptors	[107])	are	activated	by	the	endogenous	~75	amino-acid
anaphylatoxin	polypeptides	C3a	and	C5a,	generated	upon	stimulation	of	the	complement	cascade.
C3a	and	C5a	exert	their	functions	through	binding	to	their	receptors	(C3aR,	C5aR1	and	C5aR2),
causing	cell	recruitment	and	triggering	cellular	degranulation	that	contributes	to	local	inflammation.
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